CytoDyn Seeks 28.57% Stock Authorization Hike Ahead of Annual Meeting

TL;DR

**CYDY is asking for a massive share increase, signaling potential dilution ahead; vote against if you want to protect your stake.**

AI Summary

CytoDyn Inc. is holding its 2025 Annual Meeting of Stockholders on November 21, 2025, virtually, to address several critical proposals. A key item is the election of five directors to the Board. Stockholders will also vote on the advisory ratification of CBIZ CPAs P.C. as the independent auditor for fiscal year ending May 31, 2026, and an advisory vote on named executive officer compensation. Crucially, the company seeks approval to increase its authorized common stock from 1,750,000,000 to 2,250,000,000 shares, a 28.57% increase. This proposal requires the affirmative votes of a majority of outstanding shares. The Board recommends voting 'FOR' all proposals, including the share increase, and 'ONE YEAR' for the frequency of executive compensation votes. The record date for voting is September 25, 2025, with 1,259,752,684 shares of common stock outstanding as of that date.

Why It Matters

This DEF 14A filing is crucial for investors as CytoDyn Inc. proposes a significant 28.57% increase in authorized common stock, from 1.75 billion to 2.25 billion shares. Such an increase could signal future capital raises, diluting existing shareholder value, or provide flexibility for strategic transactions like acquisitions or employee incentives. For employees, executive compensation votes offer insight into governance, while customers and the broader market will watch how these decisions impact the company's financial stability and competitive positioning in the biotech sector, especially given its history of clinical trial challenges.

Risk Assessment

Risk Level: high — The proposal to increase authorized common stock from 1,750,000,000 to 2,250,000,000 shares represents a substantial 28.57% potential dilution. This significant increase, requiring a majority of outstanding shares for approval, poses a high risk of future equity offerings that could depress share price and dilute current shareholder value.

Analyst Insight

Investors should carefully consider the implications of the proposed 28.57% increase in authorized shares. If concerned about potential dilution, vote 'AGAINST' Proposal 5 to signal disapproval of this significant capital structure change.

Key Numbers

• 1,750,000,000 — Current Authorized Shares (Baseline for common stock before proposed increase)
• 2,250,000,000 — Proposed Authorized Shares (New total if Proposal 5 is approved, representing a 28.57% increase)
• 1,259,752,684 — Shares Outstanding (As of record date September 25, 2025, for voting eligibility)
• 2025-09-25 — Record Date (Date stockholders must own shares to vote at the Annual Meeting)
• 2025-11-21 — Annual Meeting Date (Date of the virtual Annual Meeting of Stockholders)
• 5 — Number of Directors (Number of directors to be elected to the Board)
• 12 — Board Meetings (Number of Board meetings held during fiscal year ended May 31, 2025)
• 75% — Director Attendance Rate (Minimum attendance rate for Board and committee meetings by directors)
• 58 — Tanya D. Urbach's Age (Age of the Board Chair)
• 73 — Karen J. Brunke's Age (Age of director Karen J. Brunke)

Key Players & Entities

• CytoDyn Inc. (company) — Registrant and company holding the Annual Meeting
• Jacob Lalezari (person) — Chief Executive Officer of CytoDyn Inc.
• Tyler Blok (person) — Corporate Secretary of CytoDyn Inc.
• Alliance Advisors LLC (company) — Proxy solicitor for CytoDyn Inc.
• CBIZ CPAs P.C. (company) — Independent registered public accounting firm for CytoDyn Inc.
• Tanya D. Urbach (person) — Board Chair and independent director of CytoDyn Inc.
• Securities and Exchange Commission (regulator) — Regulator overseeing the filing
• New York Stock Exchange (company) — Determines routine vs. non-routine proposals
• $1,750,000,000 (dollar_amount) — Current authorized shares of common stock
• $2,250,000,000 (dollar_amount) — Proposed authorized shares of common stock

FAQ

Risk Factors

• Dependence on Key Personnel and Potential for Disruption [high — regulatory]: The Company's success is heavily reliant on its key personnel, including its CEO, Jacob Lalezari, and other executive officers. The departure or unavailability of these individuals could significantly disrupt operations and hinder the Company's ability to execute its business strategy, particularly in the development and commercialization of its lead drug candidate, leronlimab. The company has experienced significant turnover in its executive and board positions in the past, increasing this risk.
• Need for Additional Financing and Dilution Risk [high — financial]: CytoDyn has historically incurred significant operating losses and has a history of negative cash flows from operations. The company anticipates continued substantial expenditures for research, development, and commercialization activities. To fund these activities, the company will likely need to raise additional capital through equity or debt financings. The proposed increase in authorized shares from 1,750,000,000 to 2,250,000,000 (a 28.57% increase) indicates a strong likelihood of future equity issuances, which could dilute existing stockholders' ownership.
• Uncertainty of Regulatory Approval for Leronlimab [high — regulatory]: The Company's primary product candidate, leronlimab, has faced significant regulatory hurdles and delays in obtaining approval from the U.S. Food and Drug Administration (FDA) for various indications. The success of the Company is substantially dependent on the successful development and commercialization of leronlimab. Any further delays, setbacks, or failure to obtain regulatory approval for leronlimab would have a material adverse effect on the Company's business, financial condition, and prospects.
• Intense Competition in the Biotechnology Sector [medium — market]: The biotechnology industry is characterized by rapid technological advancements and intense competition. CytoDyn faces competition from numerous pharmaceutical and biotechnology companies, including large, well-established companies with significant financial resources and research and development capabilities. These competitors may develop or acquire products that are more effective, safer, or less expensive than leronlimab, or that reach the market sooner.
• Reliance on Third-Party Manufacturers [medium — operational]: CytoDyn relies on third-party contract manufacturing organizations (CMOs) for the manufacturing of leronlimab. The Company's ability to manage its supply chain and ensure the quality and timely delivery of its drug product depends on the performance of these CMOs. Any disruption in the manufacturing process, quality control issues, or failure of these third parties to meet their obligations could adversely affect the Company's ability to meet market demand and regulatory requirements.
• Ongoing Litigation and Legal Proceedings [medium — legal]: The Company has been involved in various legal proceedings and investigations, which can be costly, time-consuming, and divert management's attention. Adverse outcomes in these matters could result in significant financial liabilities and reputational damage, impacting the Company's ability to operate and secure future funding.

Industry Context

CytoDyn operates in the highly competitive and rapidly evolving biotechnology sector, focusing on the development of novel therapeutics. The industry is characterized by significant R&D investment, lengthy and complex regulatory approval processes, and intense competition from both established pharmaceutical giants and emerging biotech firms. Success hinges on scientific innovation, clinical trial efficacy, and the ability to navigate regulatory pathways effectively.

Regulatory Implications

The company's primary product candidate, leronlimab, faces stringent regulatory scrutiny from bodies like the FDA. Delays or failures in obtaining regulatory approval for leronlimab would severely impact CytoDyn's future prospects. Furthermore, compliance with evolving healthcare regulations and reporting requirements is critical for ongoing operations and market access.

What Investors Should Do

1. Vote on Director Elections: Review the nominees and vote for or against their election to the Board of Directors to influence corporate governance.
2. Approve Auditor Ratification: Vote 'FOR' the ratification of CBIZ CPAs P.C. as the independent auditor to ensure financial oversight.
3. Vote on Executive Compensation: Cast an advisory vote on named executive officer compensation to express shareholder sentiment on pay practices.
4. Approve Share Increase: Carefully consider the proposal to increase authorized shares to 2,250,000,000. This requires a majority of outstanding shares and will significantly impact potential future dilution. Vote 'FOR' or 'AGAINST' based on your view of the company's future capital needs and dilution concerns.
5. Determine Executive Compensation Vote Frequency: Vote for 'ONE YEAR' for the frequency of advisory votes on executive compensation, as recommended by the Board, to align with typical corporate governance practices.

Key Dates

• 2025-09-25: Record Date — Establishes the eligibility of stockholders to vote at the Annual Meeting. Only those holding shares on this date are entitled to vote.
• 2025-11-21: 2025 Annual Meeting of Stockholders — The date for the virtual meeting where key proposals, including director elections and the share increase, will be voted upon.
• 2025-05-31: Fiscal Year End — Marks the end of the fiscal year for which the independent auditor's services are being ratified and for which the company's financial statements are presented.
• 2025-09-29: Mailing of Proxy Materials — Indicates when stockholders began receiving information about the Annual Meeting and how to vote, initiating the proxy solicitation period.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that contains detailed information about a company's annual meeting of stockholders, including proposals to be voted on, director nominations, and executive compensation. (This document is the primary source of information for the 2025 Annual Meeting of Stockholders, outlining all matters to be decided by shareholders.)

Proxy Statement

A document that a company must provide to shareholders before their annual meeting. It contains information about the matters to be voted on, such as director elections and executive compensation. (This document details the proposals, board recommendations, and voting procedures for CytoDyn's 2025 Annual Meeting.)

Authorized Shares

The maximum number of shares of stock that a corporation is legally permitted to issue, as specified in its charter or articles of incorporation. (CytoDyn is seeking to increase its authorized shares from 1,750,000,000 to 2,250,000,000, which is a critical proposal for future financing and strategic flexibility.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote at a shareholder meeting, or exercise other rights. (Sets the cutoff for determining who can vote at the November 21, 2025, Annual Meeting.)

Advisory Vote (Non-Binding)

A vote by shareholders on a particular matter, such as executive compensation, that expresses their opinion but does not legally bind the company to take any specific action. (Shareholders will have advisory votes on executive compensation and the frequency of such votes, allowing them to voice their sentiment without direct legal consequence.)

Quorum

The minimum number of shareholders or shares required to be present at a meeting for business to be legally transacted. (Prompt voting is encouraged to ensure a quorum is met for the Annual Meeting to proceed with voting on important proposals.)

Year-Over-Year Comparison

This DEF 14A filing for the 2025 Annual Meeting focuses heavily on the critical proposal to increase authorized common stock from 1,750,000,000 to 2,250,000,000 shares, a significant 28.57% increase, indicating a strong need for future capital. Unlike previous filings that might have detailed operational progress or specific clinical trial updates, this document emphasizes the procedural aspects of the annual meeting and the strategic financial implications of the share authorization. The sentiment remains bearish due to the persistent need for financing and the inherent risks associated with drug development and regulatory approvals.

Key Financial Figures

• $0.001 — only shares of common stock, par value $0.001 per share, of the Company are entitled

Filing Documents

• cydy-20251121xdef14a.htm (DEF 14A) — 770KB
• cydy-20251121xdef14a_a005.jpg (GRAPHIC) — 7KB
• cydy-20251121xdef14a_a007.jpg (GRAPHIC) — 6KB
• cydy-20251121xdef14a_bg001.jpg (GRAPHIC) — 177KB
• cydy-20251121xdef14a_bg002.jpg (GRAPHIC) — 139KB
• cydy-20251121xdef14a_cg001.jpg (GRAPHIC) — 151KB
• cydy-20251121xdef14a_cg002.jpg (GRAPHIC) — 162KB
• 0001104659-25-094518.txt ( ) — 3712KB
• cydy-20251121.xsd (EX-101.SCH) — 4KB
• cydy-20251121_def.xml (EX-101.DEF) — 5KB
• cydy-20251121_lab.xml (EX-101.LAB) — 8KB
• cydy-20251121_pre.xml (EX-101.PRE) — 6KB
• cydy-20251121xdef14a_htm.xml (XML) — 502KB

From the Filing

CytoDyn Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 CytoDyn Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. CYTODYN INC. 1111 Main Street, Suite 660 Vancouver, Washington 98660 (360) 980-8524 September 29, 2025 Dear CytoDyn Stockholder: You are cordially invited to virtually attend the 2025 Annual Meeting of Stockholders of CytoDyn Inc. (the "Company") to be held solely online via a live webcast at 9:30 a.m., Pacific Time, on November 21, 2025 at https://web.viewproxy.com/CYDY/2025. There is no physical location for the Annual Meeting. To attend and vote at the Annual Meeting, you must be a stockholder of record as of the close of business on September 25, 2025, or hold a legal proxy, as explained in the "Voting, Revocation, and Solicitation of Proxies" and "Attendance at the Annual Meeting" sections of the accompanying proxy statement. The matters to be presented for action at the Annual Meeting are (i) the election of five directors to our Board of Directors; (ii) ratification, on an advisory (non-binding) basis, of the appointment of our auditors; (iii) approval, on an advisory (non-binding) basis, of our named executive officer compensation; (iv) an advisory (nonbinding) vote on the frequency of holding an advisory vote on executive compensation; (v) a proposal to increase the total number of authorized shares of common stock from 1,750,000,000 to 2,250,000,000 shares; and (vi) a proposal for the adjournment of the Annual Meeting to solicit additional proxies, if there are insufficient votes at the Annual Meeting to approve the share increase proposal, as further described in the enclosed proxy statement. We may also act on such other business as it may properly come before the Annual Meeting. We are excited about the future of our Company. It is vitally important that your shares are represented and voted, whether or not you are able to attend the virtual meeting. We urge you to promptly vote and submit your proxy (1) via the Internet, (2) by phone, or (3) if you received your proxy materials by mail, by signing, dating, and returning the enclosed proxy card or voting instruction form in the envelope provided for your convenience. Sincerely, Jacob Lalezari Chief Executive Officer If you have any questions or require any assistance in voting your shares, please call: Alliance Advisors LLC 150 Clove Road, Suite 400, Little Falls, NJ 07424 Phone: 1-855-206-1134 Email: cydy@allianceadvisors.com CYTODYN INC. NOTICE OF ANNUAL MEETING OF STOCKHOLDERS NOVEMBER 21, 2025 You are invited to virtually attend the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of CytoDyn Inc., a Delaware corporation (the "Company"), to be held at 9:30 a.m., Pacific Time, on November 21, 2025, via a live webcast at https://web.viewproxy.com/CYDY/2025. The Board of Directors has fixed September 25, 2025 as the record date for the meeting. Only stockholders of record at the close of business on September 25, 2025, or who hold a legal proxy, are entitled to notice of, to vote at, and to virtually attend the Annual Meeting or any postponements or adjournments thereof. Please refer to the "Voting, Revocation, and Solicitation of Proxies" and "Attendance at the Annual Meeting" sections of the accompanying Proxy Statement for additional information. The Annual Meeting is being held to consider and vote on the following matters: 1. Election of five (5) directors to serve on the Board of Directors until the 2026 Annual Meeting of Stockholders, until their successors are duly elected and qualified or until their earlier death, resignation or removal; 2. Ratification, on an advisory (non-binding) basis, of the selection of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending May 31, 2026; 3. Approval, on an advisory (non-binding) basis, of our named executive officer compensation; 4. An advisory (nonbinding) vote on the frequency of holding an advisory vote on executive compensation; 5. Approval of a proposal to amend the Company's Certificate of Incorporation to increase the total number of authorized shares of common stock from 1,750,000,000 to 2,250,000,000 shares; 6. Approval of a proposal for the adjournment

View Full Filing

View this DEF 14A filing on SEC EDGAR